Rocket Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Rocket Pharmaceuticals Il CEO è Gaurav Shah, nominato in Jan2018, e ha un mandato di 6.83 anni. la retribuzione annua totale è $ 8.01M, composta da 7.8% di stipendio e 92.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.22% delle azioni della società, per un valore di $ 15.71M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 6.8 anni.
Informazioni chiave
Gaurav Shah
Amministratore delegato
US$8.0m
Compenso totale
| Percentuale dello stipendio del CEO | 7.8% |
| Mandato del CEO | 6.8yrs |
| Proprietà del CEO | 1.2% |
| Durata media del management | 3.2yrs |
| Durata media del Consiglio di amministrazione | 6.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?
Sep 23
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
Sep 15Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
Jun 28We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Jun 09Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Apr 05Rocket Pharmaceuticals' Promising Path In Gene Therapy
Mar 01Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth
Nov 07Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering
Oct 03Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate
Aug 25We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate
Jul 22Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs
Jul 08Rocket Pharma: Poised For Growth In The Rare Disease Space
Jun 30Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside
Jan 30We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely
Nov 09Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes
Oct 01Rocket earns Evercore nod after positive data for rare genetic disease
Dec 17Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial
Dec 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$258m |
| Jun 30 2024 | n/a | n/a | -US$253m |
| Mar 31 2024 | n/a | n/a | -US$249m |
| Dec 31 2023 | US$8m | US$625k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$253m |
| Jun 30 2023 | n/a | n/a | -US$249m |
| Mar 31 2023 | n/a | n/a | -US$237m |
| Dec 31 2022 | US$7m | US$598k | -US$222m |
| Sep 30 2022 | n/a | n/a | -US$199m |
| Jun 30 2022 | n/a | n/a | -US$192m |
| Mar 31 2022 | n/a | n/a | -US$172m |
| Dec 31 2021 | US$8m | US$590k | -US$169m |
| Sep 30 2021 | n/a | n/a | -US$186m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$540k | -US$140m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$89m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$480k | -US$77m |
| Sep 30 2019 | n/a | n/a | -US$85m |
| Jun 30 2019 | n/a | n/a | -US$82m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$6m | US$414k | -US$75m |
Compensazione vs Mercato: La retribuzione totale di Gaurav ($USD 8.01M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.42M ).
Compensazione vs guadagni: La retribuzione di Gaurav è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Gaurav Shah (49 yo)
6.8yrs
Mandato
US$8,013,553
Compensazione
Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Head of R&D | 6.8yrs | US$4.85m | 0.44% $ 5.7m | |
| Chief Technical Officer | 2.3yrs | US$4.38m | 0.062% $ 799.0k | |
| Chief Medical & Gene Therapy Officer | 6.8yrs | US$3.16m | 0.11% $ 1.4m | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| General Counsel | 3yrs | US$1.56m | 0.070% $ 896.9k | |
| Director of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief People Officer | 3.2yrs | Nessun dato | Nessun dato | |
| Senior VP of Clinical Safety & Chief Regulatory Officer | 4.6yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | no data | US$2.82m | 0% $ 0 | |
| Chief Commercial Operations & Revenue Officer | less than a year | Nessun dato | Nessun dato |
3.2yrs
Durata media
49yo
Età media
Gestione esperta: Il team dirigenziale di RCKT è considerato esperto (durata media dell'incarico 3.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$8.01m | 1.22% $ 15.7m | |
| Independent Director | 10.3yrs | US$399.99k | 0.13% $ 1.6m | |
| Independent Director | 6.8yrs | US$429.98k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$427.49k | 0% $ 0 | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Chairman of the Board | 6.8yrs | US$409.99k | 0.059% $ 756.6k | |
| Independent Director | 6.8yrs | US$417.49k | 0.13% $ 1.6m | |
| Independent Non-Executive Director | 2.7yrs | US$399.99k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$409.99k | 0% $ 0 | |
| Director | 6.8yrs | US$399.99k | 0.22% $ 2.8m | |
| Independent Non- Executive Director | less than a year | US$568.70k | Nessun dato |
6.8yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RCKT sono considerati esperti (durata media dell'incarico 6.8 anni).